Avandamet Bioequivalence Study Brazil - Fed Administration

EXCLUSION CRITERIA:

• The volunteer has a known hypersensitivity to the study drug or to compounds chemically related;
• History or presence of hepatic or gastrointestinal illnesses, or other condition that interferes over the drug's absorption, distribution, excretion or metabolism;
• History of neurological, endocrine, pulmonary, hamatologic, immune, brain, metabolic or cardiovascular illness;
• Hypo or hypertension of any etiologic that needs pharmacologic treatment;
• The results of the laboratory exams are out of the values considered as normal according this protocol's rules, unless that they are considered as clinically irrelevant by the investigator;
• Has history of alcohol or drugs abuse;
• History of use drug inducing and/or inhibitors of hepatic metabolism within 30 days prior to drug study administration;
• Use of MAO inhibitors two weeks before the start of treatment; - Use of inhibitors of 5-TH reuptake,
• Pregnancy or breastfeeding,
• Smoking;
• Use of regular medication within 4 weeks prior to study iniciation;
• Use of experimental drug or participation in any clinical study within 6 months prior to study iniciation.

INCLUSION CRITERIA:

• Age between 18 and 50 years;
• Body mass index ≥ 18,5 and ≤25,0, can vary up to 15% for the upper limit (18,5 to 28,75);
• Good health conditions;
• Obtain the Informed Consent's signed.